Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

273 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, Danese S; True North Study Group. Sandborn WJ, et al. N Engl J Med. 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617. N Engl J Med. 2021. PMID: 34587385 Clinical Trial.
Mesalazine is safe for the treatment of IBD.
D'Haens G, van Bodegraven AA. D'Haens G, et al. Among authors: van bodegraven aa. Gut. 2004 Jan;53(1):155. doi: 10.1136/gut.53.1.155. Gut. 2004. PMID: 14684596 Free PMC article. No abstract available.
Cost-effectiveness and cost-utility of optimized mercaptopurine treatment versus placebo in ulcerative colitis patients: The randomized controlled OPTIC trial.
Löwenberg M, van Barreveld M, Volkers A, van Gennep S, Duijvestein M, van Bodegraven AA, Hulshoff MS, Jansen JM, van Asseldonk D, West R, D'Haens G, de Boer N, Dijkgraaf MGW. Löwenberg M, et al. Among authors: van bodegraven aa. United European Gastroenterol J. 2024 Nov;12(9):1256-1265. doi: 10.1002/ueg2.12661. Epub 2024 Oct 13. United European Gastroenterol J. 2024. PMID: 39400525 Free PMC article. Clinical Trial.
A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial.
van Linschoten RCA, Jansen FM, Pauwels RWM, Smits LJT, Atsma F, Kievit W, de Jong DJ, de Vries AC, Boekema PJ, West RL, Bodelier AGL, Gisbertz IAM, Wolfhagen FHJ, Römkens TEH, Lutgens MWMD, van Bodegraven AA, Oldenburg B, Pierik MJ, Russel MGVM, de Boer NK, Mallant-Hent RC, Ter Borg PCJ, van der Meulen-de Jong AE, Jansen JM, Jansen SV, Tan ACITL, van der Woude CJ, Hoentjen F; LADI study group, the Dutch Initiative on Crohn, Colitis (ICC). van Linschoten RCA, et al. Among authors: van bodegraven aa. Dig Dis Sci. 2024 Jun;69(6):2165-2174. doi: 10.1007/s10620-024-08410-z. Epub 2024 Apr 9. Dig Dis Sci. 2024. PMID: 38594435 Free PMC article. Clinical Trial.
Dynamic Prediction of Advanced Colorectal Neoplasia in Inflammatory Bowel Disease.
Wijnands AM, Penning de Vries BBL, Lutgens MWMD, Bakhshi Z, Al Bakir I, Beaugerie L, Bernstein CN, Chang-Ho Choi R, Coelho-Prabhu N, Graham TA, Hart AL, Ten Hove JR, Itzkowitz SH, Kirchgesner J, Mooiweer E, Shaffer SR, Shah SC, Elias SG, Oldenburg B; Dutch Initiative on Crohn and Colitis (ICC). Wijnands AM, et al. Clin Gastroenterol Hepatol. 2024 Aug;22(8):1697-1708. doi: 10.1016/j.cgh.2024.02.014. Epub 2024 Feb 29. Clin Gastroenterol Hepatol. 2024. PMID: 38431223 Free article.
Exploring the role of oxidative stress and the effect of N-acetylcysteine in thiopurine-induced liver injury in inflammatory bowel disease: A randomized crossover pilot study.
van Asseldonk DP, Crouwel F, Seinen ML, Scheffer PG, Veldkamp AI, de Boer NK, Lissenberg-Witte B, Peters GJ, van Bodegraven AA. van Asseldonk DP, et al. Among authors: van bodegraven aa. Basic Clin Pharmacol Toxicol. 2024 Apr;134(4):507-518. doi: 10.1111/bcpt.13978. Epub 2024 Jan 29. Basic Clin Pharmacol Toxicol. 2024. PMID: 38284479 Clinical Trial.
273 results